Arcticzymes Technologies ASA Asset Resilience Ratio
Arcticzymes Technologies ASA asset resilience ratio. Arcticzymes Technologies ASA (AZT) has an Asset Resilience Ratio of 20.77% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AZT total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Arcticzymes Technologies ASA (2016–2025)
Asset resilience ratio of Arcticzymes Technologies ASA from 2016 to 2025. This chart shows how Arcticzymes Technologies ASA's Asset Resilience Ratio has changed over time. See how much free cash does Arcticzymes Technologies ASA generate to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Arcticzymes Technologies ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AZT total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 0% |
| Short-term Investments | Nkr78.75 Million | 20.77% |
| Total Liquid Assets | Nkr78.75 Million | 20.77% |
Asset Resilience Insights
- Good Liquidity Position: Arcticzymes Technologies ASA maintains a healthy 20.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Arcticzymes Technologies ASA Industry Peers by Asset Resilience Ratio
Compare Arcticzymes Technologies ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Arcticzymes Technologies ASA Asset Resilience Ratio by Year (2016–2025)
Arcticzymes Technologies ASA asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Arcticzymes Technologies ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.25% | Nkr264.72 Million ≈ $27.86 Million |
Nkr361.41 Million ≈ $38.03 Million |
+2.39pp |
| 2024-12-31 | 70.86% | Nkr243.94 Million ≈ $25.67 Million |
Nkr344.26 Million ≈ $36.23 Million |
+17.55pp |
| 2023-12-31 | 53.31% | Nkr180.89 Million ≈ $19.04 Million |
Nkr339.32 Million ≈ $35.71 Million |
-23.22pp |
| 2022-12-31 | 76.53% | Nkr244.16 Million ≈ $25.69 Million |
Nkr319.04 Million ≈ $33.57 Million |
+5.99pp |
| 2021-12-31 | 70.54% | Nkr200.42 Million ≈ $21.09 Million |
Nkr284.11 Million ≈ $29.90 Million |
+7.38pp |
| 2020-12-31 | 63.17% | Nkr140.18 Million ≈ $14.75 Million |
Nkr221.91 Million ≈ $23.35 Million |
+22.85pp |
| 2019-12-31 | 40.32% | Nkr31.29 Million ≈ $3.29 Million |
Nkr77.61 Million ≈ $8.17 Million |
-6.24pp |
| 2018-12-31 | 46.55% | Nkr31.66 Million ≈ $3.33 Million |
Nkr68.02 Million ≈ $7.16 Million |
-3.05pp |
| 2017-12-31 | 49.60% | Nkr30.59 Million ≈ $3.22 Million |
Nkr61.68 Million ≈ $6.49 Million |
-17.60pp |
| 2016-12-31 | 67.19% | Nkr57.67 Million ≈ $6.07 Million |
Nkr85.83 Million ≈ $9.03 Million |
-- |
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids… Read more